Halozyme Therapeutics, Inc. Sustainability Profile
Halozyme Therapeutics, Inc., a leading biotechnology company headquartered in the United States, has been at the forefront of innovative drug delivery solutions since its founding in 1998. Specialising in the development of enzyme-based therapies, Halozyme focuses on enhancing the efficacy of biologic drugs through its proprietary Hylenex® recombinant technology, which facilitates the subcutaneous delivery of therapeutics. With a strong presence in the biopharmaceutical industry, Halozyme has established strategic partnerships with major pharmaceutical companies, significantly expanding its market reach. Notable achievements include the successful integration of its technology into various therapeutic areas, including oncology and diabetes care. As a pioneer in the field, Halozyme continues to drive advancements in drug delivery, positioning itself as a key player in the evolving landscape of biotechnology.
DitchCarbon Score
How does Halozyme Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Halozyme Therapeutics, Inc.'s score of 25 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Halozyme Therapeutics, Inc.'s reported carbon emissions
Halozyme Therapeutics, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As of now, Halozyme has not inherited any emissions data from a parent or related organization, nor does it have any commitments to industry-standard initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). In the context of the biopharmaceutical industry, companies are increasingly focusing on sustainability and climate commitments. However, without specific data or targets, it is unclear how Halozyme Therapeutics aligns with these broader industry trends.
How Carbon Intensive is Halozyme Therapeutics, Inc.'s Industry?
How Carbon Intensive is Halozyme Therapeutics, Inc.'s Location?
Halozyme Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Halozyme Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
